Efficacy of 0.05%topical everolimus in the treatment of adenoma sebaceum in tuberous sclerosis
Phase 2
Recruiting
- Conditions
- adenoma sebaceum
- Registration Number
- TCTR20180820002
- Lead Sponsor
- Dermatology division, Department of internal medicine, King Chulalongkorn Memorial Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 15
Inclusion Criteria
-patients with adenoma sebaceum
Exclusion Criteria
-pregnancy
-allergic reaction to everolimus
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method improvement of adenoma sebaceum 0,4,8,12,24 weeks Photograph
- Secondary Outcome Measures
Name Time Method safety of 0.05% topical everolimus 0,12 weeks blood test for complete blood count ,renal function test